Plain-English translation of NCT05316805 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a large national research study that will follow up to 100,000 patients with type 2 inflammatory skin diseases, including eczema and prurigo nodularis. Researchers want to learn how different treatments are working in real-world practice and understand what helps patients feel better. By collecting information from many patients across China, doctors hope to create better, more consistent treatment guidelines.
Right now, treatment for inflammatory skin conditions varies widely, and doctors don't have enough information about which treatments work best or are safest in everyday practice. This study will help fill that gap so that all patients can receive the most effective and standardized care.
You likely qualify if…
You likely don't qualify if…
As a participant, you would share your medical history, current symptoms, and treatment information with the research team at your hospital. You may complete questionnaires about your skin condition and how it affects your daily life. The study is observational, meaning researchers will monitor your condition and treatments over time rather than assigning you to a new medication — they're simply learning from what already works in practice.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China
Sponsor
Peking University First Hospital
Enrollment target
~100,000 participants
Started
August 2021
Primary completion
December 2031
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yang Wang, Doctor
Peking University First Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.